• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cancer: Antitumour immunity gets a boost.癌症：抗肿瘤免疫力增强。
Nature. 2014 Nov 27;515(7528):496-8. doi: 10.1038/515496a.
2
Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem.肿瘤异质性与肿瘤免疫：一个先有鸡还是先有蛋的问题。
Trends Immunol. 2016 Jun;37(6):349-351. doi: 10.1016/j.it.2016.04.008. Epub 2016 May 8.
3
PD-1-targeted immunotherapy: recent clinical findings.靶向程序性死亡受体 1（PD-1）的免疫疗法：近期临床研究结果
Clin Adv Hematol Oncol. 2012 Oct;10(10):674-5.
4
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.癌症免疫疗法迷你综述：对PD-1/PD-L1通路的分子理解及免疫检查点的转化性阻断
Int J Mol Sci. 2016 Jul 18;17(7):1151. doi: 10.3390/ijms17071151.
5
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.肿瘤学中与使用免疫检查点抑制剂相关的感染并发症：抗PD-1治疗后结核病复发
Clin Microbiol Infect. 2018 Mar;24(3):216-218. doi: 10.1016/j.cmi.2017.12.003. Epub 2017 Dec 18.
6
Nivolumab Gets FDA Nod for Bladder Cancer.纳武利尤单抗获 FDA 批准用于膀胱癌。
Cancer Discov. 2017 Apr;7(4):OF7. doi: 10.1158/2159-8290.CD-NB2017-021. Epub 2017 Feb 9.
7
Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.鉴定用于肿瘤治疗的单克隆抗体在PD-L1上pH依赖性结合的热点。
Signal Transduct Target Ther. 2020 Aug 24;5(1):158. doi: 10.1038/s41392-020-00254-z.
8
Targeting PD-L1 Protein: Translation, Modification and Transport.靶向程序性死亡受体配体1蛋白：翻译、修饰与转运
Curr Protein Pept Sci. 2019;20(1):82-91. doi: 10.2174/1389203719666180928105632.
9
The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.PD-1/PD-L1轴在尿路上皮膀胱癌发病机制中的作用及其作为治疗靶点的潜力评估
Future Oncol. 2016 Mar;12(5):595-600. doi: 10.2217/fon.15.337. Epub 2016 Feb 1.
10
Visualizing microbiome-immune system interplay.可视化微生物群与免疫系统的相互作用。
Immunotherapy. 2019 Feb;11(2):63-67. doi: 10.2217/imt-2018-0138.

引用本文的文献

1
The immunomodulatory role of tumor-initiating cells in digestive system tumors: from mechanisms to therapy.肿瘤起始细胞在消化系统肿瘤中的免疫调节作用：从机制到治疗
Front Immunol. 2025 Jul 24;16:1621464. doi: 10.3389/fimmu.2025.1621464. eCollection 2025.
2
A New Protein-Ligand Trapping System to Rapidly Screen and Discover Small-Molecule Inhibitors of PD-L1 from Natural Products.一种新型蛋白质-配体捕获系统，用于从天然产物中快速筛选和发现PD-L1的小分子抑制剂。
Molecules. 2025 Apr 14;30(8):1754. doi: 10.3390/molecules30081754.
3
Shared neoantigens for cancer immunotherapy.用于癌症免疫治疗的共享新抗原。
Mol Ther Oncol. 2025 Mar 28;33(2):200978. doi: 10.1016/j.omton.2025.200978. eCollection 2025 Jun 18.
4
Docosahexaenoic acid (DHA) impairs hypoxia-induced cellular and exosomal overexpression of immune-checkpoints and immunomodulatory molecules in different subtypes of breast cancer cells.二十二碳六烯酸（DHA）可抑制不同亚型乳腺癌细胞中缺氧诱导的免疫检查点和免疫调节分子的细胞及外泌体过表达。
BMC Nutr. 2024 Mar 4;10(1):41. doi: 10.1186/s40795-024-00844-y.
5
PD-L1/PD-L1 signalling promotes colorectal cancer cell migration ability through RAS/MEK/ERK.PD-L1/PD-L1 信号通过 RAS/MEK/ERK 促进结直肠癌细胞迁移能力。
Clin Exp Pharmacol Physiol. 2022 Dec;49(12):1281-1293. doi: 10.1111/1440-1681.13717. Epub 2022 Sep 15.
6
PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors.程序性死亡配体1结合物：通过整合下一代噬菌体展示数据和不同的肽描述符来鉴定程序性细胞死亡配体1结合肽
Front Microbiol. 2022 Jul 15;13:928774. doi: 10.3389/fmicb.2022.928774. eCollection 2022.
7
Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.结肠癌中缺氧相关亚型的鉴定、预后模型的建立及肿瘤微环境浸润特征
Front Genet. 2022 Jun 17;13:919389. doi: 10.3389/fgene.2022.919389. eCollection 2022.
8
A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes.具有免疫相关基因的晚期肾细胞癌（RCC）的有前途的预后风险模型。
BMC Cancer. 2022 Jun 23;22(1):691. doi: 10.1186/s12885-022-09755-2.
9
Overexpression of PD-L1 causes germ cells to slough from mouse seminiferous tubules via the PD-L1/PD-L1 interaction.PD-L1 的过表达导致小鼠生精小管中的生殖细胞脱落，这是通过 PD-L1/PD-L1 相互作用实现的。
J Cell Mol Med. 2022 May;26(10):2908-2920. doi: 10.1111/jcmm.17305. Epub 2022 Apr 5.
10
Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.内分泌自身抗体决定免疫检查点抑制剂引起的内分泌疾病：一项前瞻性研究。
J Clin Endocrinol Metab. 2022 Jun 16;107(7):1976-1982. doi: 10.1210/clinem/dgac161.

本文引用的文献

1
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.检查点阻断癌症免疫疗法靶向肿瘤特异性突变抗原。
Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.
2
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.通过质谱分析与外显子组测序相结合预测免疫原性肿瘤突变。
Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001.
3
PD-1 blockade induces responses by inhibiting adaptive immune resistance.程序性死亡受体1（PD-1）阻断通过抑制适应性免疫抵抗来诱导反应。
Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.
4
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.癌症患者对抗PD-L1抗体MPDL3280A反应的预测性相关因素。
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
5
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.MPDL3280A（抗 PD-L1）治疗可导致转移性膀胱癌的临床活性。
Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.
6
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.突变新抗原表位的基因组和生物信息学分析揭示了预测抗癌免疫原性的新规则。
J Exp Med. 2014 Oct 20;211(11):2231-48. doi: 10.1084/jem.20141308. Epub 2014 Sep 22.
7
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.派姆单抗治疗伊匹单抗难治性晚期黑色素瘤的抗程序性死亡受体 1 治疗：一项 I 期试验的随机剂量比较队列。
Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.
8
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.纳武利尤单抗治疗晚期黑色素瘤患者的生存、持久肿瘤缓解和长期安全性。
J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3.
9
Immune modulation in cancer with antibodies.癌症的抗体免疫调节。
Annu Rev Med. 2014;65:185-202. doi: 10.1146/annurev-med-092012-112807. Epub 2013 Oct 30.
10
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.拉罗替尼（anti-PD-1）治疗黑色素瘤的安全性和肿瘤应答。
N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.

Cancer: Antitumour immunity gets a boost.

作者信息

Wolchok Jedd D, Chan Timothy A

机构信息

Department of Medicine and the Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

Department of Radiation Oncology and the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center.

出版信息

Nature. 2014 Nov 27;515(7528):496-8. doi: 10.1038/515496a.

DOI:10.1038/515496a
PMID:25428495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6592276/
Abstract
摘要